Novel application of selepravastatin

A technology with a new use and route of administration, applied in the new use field of selepravatide, which can solve the problems of poor safety and easy recurrence of membranous nephropathy

Inactive Publication Date: 2021-03-09
ZHAOKE PHARMA GUANGZHOU
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In order to solve the problems in the prior art that the safety of glucocorticoids in the treatment of membranous nephropathy is poor, and it is easy to relapse after drug withdrawal or reduction, the present invention discovers a new application of selepravatide, and the purpose of realization is to treat membranous nephropathy. Kidney disease provides a new treatment, improves drug safety

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel application of selepravastatin
  • Novel application of selepravastatin
  • Novel application of selepravastatin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Embodiment 1: The present invention discovers the new application of selepravatide, the application of selepravatide in the preparation of medicines for treating nephropathy, specifically, as the application of preparation of medicines for treating membranous nephropathy, the application of selepravatide in the preparation of When preparing a drug for treating membranous nephropathy, the podocytes are stimulated to express MC1R, thereby reducing proteinuria and oxidative stress, and simultaneously reducing systolic blood pressure. The route of administration can be any one of intravenous injection, subcutaneous injection and inhalation.

[0014] Use of the present invention is described below by experiment:

[0015] 1. Basic information of selepravatide:

[0016] Generic name: selepravatide gel (CDE has confirmed the name)

[0017] English name: Cyslyprovatide Gel

[0018] Pinyin: Silaipufatai Ningjiao

[0019] Chemical name: (acetyl-cysteine-lysine-proline-valine-a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a new application of selepravastatin, namely an application of selepravastatin in preparation of a medicine for treating nephropathy. The application has the advantages that anew medicine for treating the nephropathy is provided, the effect of treating the membranous nephropathy is achieved through the immune effect, and finally animal experiments prove that the selaprivapeptide can reduce total urinary protein, urinary albumin and systolic pressure of membranous nephropathy model animals, so that the selaprivapeptide is a new immune agent and a novel therapeutic meansfor treating the membranous nephropathy.

Description

technical field [0001] The invention belongs to the technical field of medicine, and specifically relates to a new application of selepravatide. Background technique [0002] Membranous nephropathy (MN) accounts for 20% to 35% of primary nephrotic syndrome (NS), and is one of the common pathological types of nephrotic syndrome at home and abroad. MN is a pathological diagnosis. There are often numerous and regular immune complexes on the epithelial side of the glomerular basement membrane (GBM) as its pathological feature. According to the etiology, it can be divided into idiopathic membranous nephropathy (IMN) and secondary membranous nephropathy (SMN). IMN immunofluorescence is often dominated by IgG4, with c3 in a granular form along the GBM. If the immunofluorescence is dominated by IgG1 and (or) IgG2, and other conditions such as C1q and (or) C4 deposition appear, SMN should be carefully excluded. The current treatment options are mainly divided into conservative tre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/08A61P13/12
CPCA61K38/08A61P13/12
Inventor 李小羿戴向荣殷雷陈程
Owner ZHAOKE PHARMA GUANGZHOU
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap